Inventor · disambiguated record
Mark A. Varney
Also filed as: VARNEY MARK · VARNEY MARK A · VARNEY MARK ANDREW
16 granted patents·16 pending applications·120 citations·filing 1999–2025
91Inventor score
Files withSEPRACOR INC7SUNOVION PHARMACEUTICALS INC7PGI DRUG DISCOVERY LLC4NEUROLIXIS3PF MEDICAMENT3
Top patents by PatentIndex Score
32 records- 0191US8053603B2Tetralone-based monoamine reuptake inhibitorsSUNOVION PHARMACEUTICALS INC·Filed 2006·Granted Nov 8, 2011·24 cites·23 claims
- 0291US6656957B1Pyridine derivativesNOVARTIS AG·Filed 2000·Granted Dec 2, 2003·55 cites·8 claims
- 0389US7884124B2Fluoro-substituted inhibitors of D-amino acid oxidaseSEPRACOR INC·Filed 2007·Granted Feb 8, 2011·9 cites·30 claims
- 0485US11090298B2Method for treating movement disorders with befiradolPF MEDICAMENT·Filed 2019·Granted Aug 17, 2021·2 cites·7 claims
- 0578US6956049B1Methods of modulating processes mediated by excitatory amino acid receptorsMERCK & CO INC·Filed 1999·Granted Oct 18, 2005·24 cites·7 claims
- 0677US8669291B2Phenyl substituted cycloalkylamines as monoamine reuptake inhibitorsSHAO LIMING·Filed 2008·Granted Mar 11, 2014·2 cites·19 claims
- 0775US10548885B2Method for treating movement disorders with befiradolPF MEDICAMENT·Filed 2015·Granted Feb 4, 2020·2 cites·17 claims
- 0870US12472169B2Method for treating movement disorders with befiradolPF MEDICAMENT·Filed 2021·Granted Nov 18, 2025·0 cites·20 claims
- 0969US8877975B2Cycloalkylamines as monoamine reuptake inhibitorsSHAO LIMING·Filed 2010·Granted Nov 4, 2014·1 cites·23 claims
- 1066US9586888B2Phenyl substituted cycloalkylamines as monoamine reuptake inhibitorsSUNOVION PHARMACEUTICALS INC·Filed 2014·Granted Mar 7, 2017·0 cites·27 claims
- 1165US9868718B2Cycloalkylamines as monoamine reuptake inhibitorsSUNOVION PHARMACEUTICALS INC·Filed 2014·Granted Jan 16, 2018·0 cites·2 claims
- 1264US8329950B2Process for preparation of trans 4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1NapthalenamineCARON JUDY·Filed 2012·Granted Dec 11, 2012·1 cites·13 claims
- 1364US2025129035A1Compounds for the treatment of a central nervous system disease or disorderPGI DRUG DISCOVERY LLC·Filed 2024·Application pending·0 cites
- 1463US2017204050A1Phenyl substituted cycloalkylamines as monoamine reputake inhibitorsSUNOVION PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 1560US2007203111A1Cycloalkylamines as monoamine reuptake inhibitorsSEPRACOR INC·Filed 2007·Application pending·0 cites
- 1659US2014315910A1Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive DisordersSUNOVION PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 1758US2025388558A1Compounds for the treatment of a central nervous system disease or disorderCORETERRA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1857US10562878B2Cycloalkylamines as monoamine reuptake inhibitorsSUNOVION PHARMACEUTICALS INC·Filed 2017·Granted Feb 18, 2020·0 cites·26 claims
- 1956US11974992B2Use of serotonin 5-HT1A receptor agonists to treat diseases associated with sudden unexpected death in epilepsyNEUROLIXIS·Filed 2022·Granted May 7, 2024·0 cites·3 claims
- 2056US2008293726A1Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive DisordersSEPRACOR INC·Filed 2006·Application pending·0 cites
- 2156US2025304546A1Compounds for the treatment of a central nervous system disease or disorderPGI DRUG DISCOVERY LLC·Filed 2025·Application pending·0 cites
- 2255US2013065904A1Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive DisordersSUNOVION PHARMACEUTICALS INC·Filed 2012·Application pending·0 cites
- 2351US2025236602A1Compounds for the treatment of a central nervous system disease or disorderPGI DRUG DISCOVERY LLC·Filed 2025·Application pending·0 cites
- 2450US2008058395A1Fused heterocyclic inhibitors of D-amino acid oxidaseSEPRACOR INC·Filed 2007·Application pending·0 cites
- 2550US2025295648A1Method for treating l-dopa-induced dyskinesia, parkinson's disease, or parkinson's disease motor disability using befiradolNEUROLIXIS INC·Filed 2025·Application pending·0 cites
- 2647US10562853B2Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptorsNEUROLIXIS·Filed 2017·Granted Feb 18, 2020·0 cites·29 claims
- 2747US2008175903A1Treatment of anxiety with eszopicloneSEPRACOR INC·Filed 2007·Application pending·0 cites
- 2846US2025243173A1Compounds for the treatment of a central nervous system disease or disorderPGI DRUG DISCOVERY LLC·Filed 2025·Application pending·0 cites
- 2942US2001056084A1MGluR5 antagonists for the treatment of pain and anxietyFiled 2001·Application pending·0 cites
- 3042US2009111818A1Combinations of Eszopiclone and O-Desmethylvenlafaxine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive DisordersSEPRACOR INC·Filed 2006·Application pending·0 cites
- 3142US2009111817A1Combinations of Eszopiclone and an AntidepressantSEPRACOR INC·Filed 2006·Application pending·0 cites
- 3240US11191758B2Use of selective serotonin 5-HT1A receptor agonists for treating side-effects of VMAT inhibitorsNEUROLIXIS·Filed 2018·Granted Dec 7, 2021·0 cites·6 claims
Join the waitlist — get patent alerts
Get an alert when Mark A. Varney files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →